<DOC>
	<DOCNO>NCT01471054</DOCNO>
	<brief_summary>To evaluate safety efficacy dexamethasone intravitreal implant ( Ozurdex ) compare safety efficacy intravitreal bevacizumab eye macular edema plaque radiotherapy uveal melanoma .</brief_summary>
	<brief_title>Dexamethasone Intravitreal Implant Treatment Macular Edema After Plaque Radiotherapy Uveal Melanoma</brief_title>
	<detailed_description>Plaque radiotherapy commonly use method treatment small medium-sized uveal melanoma . Macular edema one common cause visual loss plaque radiotherapy report 70 % patient posterior uveal melanoma . Different method propose treatment post-radiation macular edema include periocular steroid , intravitreal steroid , intravitreal vascular endothelial growth factor ( VEGF ) inhibitor , photodynamic therapy , macular laser photocoagulation . Injection intravitreal triamcinolone ( form steroid ) find useful treatment different form macular edema associate considerable rate increase intraocular pressure ( glaucoma ) . Dexamethasone potent triamcinolone safely inject directly vitreous cavity ( intravitreal injection ) unfortunately use form intravitreal injection practical due short half-life intraocular dexamethasone ( 3 hour ) . Within past several year , tiny drug delivery system develop allow sustain release minute amount steroid back part ( vitreous cavity ) eye , implant vitreous cavity . Ozurdex biodegradable dexamethasone intravitreal implant show well-tolerated effective 6 month reduce vision loss improve visual outcome eye different type macular edema include secondary diabetic retinopathy retinal vein occlusion . In study investigator would like evaluate safety effectiveness Ozurdex ( dexamethasone intravitreal implant ) treatment macular edema develop plaque radiotherapy uveal melanoma .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion criterion : 1 . Patient age 18 year . 2 . Uveal melanoma treat I125 plaque radiotherapy . 3 . Visual acuity 20/40 20/400 secondary postradiation macular edema . 4 . Central subfield retinal thickness &gt; 300 micron . 5 . Duration macular edema &lt; 12 month . 6 . No potential contributing cause decrease vision macular edema . Exclusion criterion : 1 . Visual acuity worse 20/400 good 20/40 . 2 . Monocular patient poor vision nonstudy eye ( &lt; 20/80 ) . 3 . History vitrectomy surgery . 4 . Panretinal photocoagulation intraocular surgery within 3 month enrollment . 5 . Concomitant previous radiation optic neuropathy . 6 . Use periocular , intravitreal , systemic steroid within 6 month enrollment study eye . 7 . Use intravitreal VEGF antagonist within 6 week enrollment . 8 . History ocular hypertension glaucoma , IOP &gt; 21 mmHg . 9 . History steroidinduced glaucoma either eye . 10 . Active ocular infection history herpetic eye infection . 11 . Clinically significant epiretinal membrane study eye . 12 . Iris neovascularization study eye . 13 . Clinically significant medium opacity prevent acquisition goodquality OCT study eye . 14 . Aphakia anterior chamber intraocular lens . 15 . Poorly control diabetes ( Hemoglobin A1c level &gt; 13 % ) . 16 . Poorly control hypertension ( Systolic pressure &gt; 160 mm Hg diastolic pressure &gt; 90 mm Hg ) . 17 . Pregnancy ( woman childbearing age negative pregnancy test use contraception ) . 18 . Presence ocular condition opinion one investigator prevent least 2 line improvement bestcorrected visual acuity . 19 . Interval plaque radiotherapy uveal melanoma intend date dexamethasone intravitreal implant le 6 month . 20 . Evidence activity inadequate regression treat uveal melanoma plaque radiotherapy ( base judgment study investigator ) . 21 . Known allergy hypersensitivity study medication component . 22 . History prior myocardial infarction stroke .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Plaque radiotherapy</keyword>
	<keyword>Brachytherapy</keyword>
	<keyword>Macular edema</keyword>
	<keyword>Cystoid macular edema</keyword>
	<keyword>Uveal melanoma</keyword>
	<keyword>Radiation maculopathy</keyword>
	<keyword>Radiation retinopathy</keyword>
	<keyword>Ozurdex</keyword>
	<keyword>Dexamethasone intravitreal implant</keyword>
</DOC>